Pharmasset, Inc. (NASDAQ: VRUS)

Gilead Sciences Inc. said it has agreed to buy Pharmasset Inc. in a deal valued at about $11 billion. The Foster City-based biopharmaceutical company (NASDAQ:GILD) said it will pay $137 a share for Princeton, N.J.-based Pharmasset (NASDAQ:VRUS). That is about 89 percent above Pharmasset's closing price on Friday of $72.67. The deal is expected to speed development of treatments for hepatitis C, an area where Parmasset last month expanded a trial of an oral treatment it is developing.

Gilead already has seven unique molecules in development for the treatment of the disease.

Gilead said it is paying about $10.4 billion now for Parmasset's shares but the eventual cost of the deal could reach $11 billion, including options.

If you are a current shareholder and would like to discuss your options of exercising your rights as a shareholder, which include ensuring that the company is getting the highest possible price for the company, and that the board of directors will act in the best interest of the shareholders, please contact us.

Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.